Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Frontage HoldingsFGHQF 56 EV-to-EBITDA is 21.57 as of Aug. 21, 2026, which is 102% above its 10-year median of 10.67. GuruFocus rates FGHQF with a GF Score™ of 56/100 and a GF Value™ of $0.23 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 406 Biotechnology companies, Frontage Holdings ranks worse than 63.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Frontage Holdings's enterprise value is $412.8 Mil.
Frontage Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $19.1 Mil. Therefore, Frontage Holdings's EV-to-EBITDA for today is 21.57.
The historical rank and industry rank for Frontage Holdings's EV-to-EBITDA or its related term are showing as below:
FGHQF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.22 Med: 10.67 Max: 72.88
Current: 21.79
During the past 10 years, the highest EV-to-EBITDA of Frontage Holdings was 72.88. The lowest was 4.22. And the median was 10.67.
FGHQF's EV-to-EBITDA is ranked worse than 63.3% of 406
companies
in the Biotechnology industry
Industry Median: 14.4
vs FGHQF: 21.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Frontage Holdings's PE Ratio (TTM) for today is calculated as:
Frontage Holdings's share price for today is $0.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Frontage Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FGHQF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Frontage Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's EV-to-EBITDA falls into.
Frontage Holdings's current Enterprise Value is $412.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $19.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings (FGHQF) has a EV-to-EBITDA of 21.57 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Frontage Holdings. This is 102% above median its historical median of 10.67. Over the past decade, Frontage Holdings' EV-to-EBITDA has ranged from 4.22 to 72.88. According to the industry distribution chart, Frontage Holdings ranks #257 out of 406 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Frontage Holdings' EV-to-EBITDA too high?
Frontage Holdings' current EV-to-EBITDA of 21.57 is 102% above median its 10-year median of 10.67. Over the past 10 years, this metric has ranged from a low of 4.22 to a high of 72.88. The Biotechnology industry median EV-to-EBITDA is 14.40. Frontage Holdings' value of 21.57 is 49.8% above this industry median. Based on the distribution chart, Frontage Holdings ranks #257 out of 406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Frontage Holdings has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #257 out of 406 companies for EV-to-EBITDA. This places Frontage Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 14.40. Frontage Holdings' value of 21.57 is 49.8% above this benchmark. Historically, Frontage Holdings' own EV-to-EBITDA has ranged from 4.22 to 72.88 over the past decade. While the company's 10-year median is 10.67 vs. the industry median of 14.40, Frontage Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontage Holdings's current EV-to-EBITDA of 21.57 is 49.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Frontage Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontage Holdings's current EV-to-EBITDA is 21.57, which is 102% above median its own 10-year median of 10.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (FGHQF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.23, compared to a current price of $0.15 — trading 34.8% below its estimated fair value. The current EV-to-EBITDA is 21.57, which is 102% above median its 10-year median of 10.67 and 49.8% above the Biotechnology industry median of 14.40. Frontage Holdings' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Frontage Holdings (FGHQF), the current EV-to-EBITDA is 21.57 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (FGHQF) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of $0.15 is trading 34.8% below its estimated GF Value™ of $0.23.
GuruFocus considers Frontage Holdings to be Significantly Undervalued.
Key valuation signals for FGHQF:
EV-to-EBITDA: 21.57 (102% above median its 10-year median of 10.67)
GF Value™: $0.23 vs. price of $0.15 (34.8% below fair value)
Industry Position: 49.8% above the Biotechnology median (#257 of 406)
No single metric tells the full story. See the FGHQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
56GF Score
Get the complete analysis for FGHQF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FGHQF has been successfully added to your 
